Security Snapshot

Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) Institutional Ownership

CUSIP: 03828A101

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

50

Shares (Excl. Options)

58,883,039

Price

$0.10

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
APLT
Shares outstanding
143,223,667
Price per share
$0.10
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
58,883,039
Total reported value
$5,929,909
% of total 13F portfolios
0%
Share change
-35,826,681
Value change
-$23,764,068
Number of holders
50
Price from insider filings
$0.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • APLT - Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 03828A101.
  • 50 institutions reported positions in Q4 2025.
  • 12 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 69 to 50 between Q3 2025 and Q4 2025.
  • Reported value moved from $57,199,408 to $5,929,909.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 50 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 03828A101?
CUSIP 03828A101 identifies APLT - Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
T. Rowe Price Investment Management, Inc. 15% +13% $12,946,856 +$1,644,911 21,403,300 +15% T. Rowe Price Investment Management, Inc. 30 Sep 2025
Alyeska Investment Group, L.P. 5.8% $2,615,924 6,707,497 Alyeska Investment Group, L.P. 31 Dec 2024
ALEXANDRIA REAL ESTATE EQUITIES, INC. 4.3% $1,755,000 6,500,000 Alexandria Real Estate Equities, Inc. 11 Dec 2025
Propel Bio Management, LLC 4.2% $1,564,002 6,015,394 Propel Bio Management, LLC 29 Dec 2025
Venrock Healthcare Capital Partners III, L.P. 4.1% -58% $2,171,407 -$2,432,661 5,567,709 -53% Venrock Healthcare Capital Partners III, L.P. 31 Mar 2025
BlackRock, Inc. 3.7% -54% $1,003,183 -$783,523 5,219,475 -44% BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 3.3% -34% $1,473,225 -$359,492 4,734,013 -20% The Vanguard Group 30 Jun 2025
Schonfeld Strategic Advisors LLC 3.3% -53% $1,823,678 -$1,596,482 4,676,097 -47% Schonfeld Strategic Advisors LLC 31 Mar 2025
PERCEPTIVE ADVISORS LLC 2.4% $1,115,400 2,860,000 Perceptive Advisors LLC 31 Dec 2024
MORGAN STANLEY 2.5% -64% $1,114,983 -$2,323,072 2,858,931 -68% Morgan Stanley 31 Jan 2025
FRANKLIN RESOURCES INC 1.7% -70% $781,326 -$1,871,029 2,003,400 -71% Franklin Resources, Inc. 31 Dec 2024
JANUS HENDERSON GROUP PLC 0% -104% $13,958 -$4,706,957 35,791 -100% JANUS HENDERSON GROUP PLC 31 Dec 2024

As of 31 Dec 2025, 50 institutional investors reported holding 58,883,039 shares of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT). This represents 41% of the company’s total 143,223,667 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) together control 40% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
T. Rowe Price Investment Management, Inc. 15% 21,747,844 +1.6% 0% $2,175,000
VANGUARD GROUP INC 4.4% 6,353,018 +25% 0% $635,302
Knoll Capital Management, LLC 4.2% 6,050,000 -22% 0.28% $605,000
DELTEC ASSET MANAGEMENT LLC 2.7% 3,847,449 0.06% $384,745
BlackRock, Inc. 2.3% 3,251,462 -15% 0% $325,146
RENAISSANCE TECHNOLOGIES LLC 1.9% 2,706,156 0% $270,616
Pathstone Holdings, LLC 1.8% 2,643,540 0% 0% $305,065
JANE STREET GROUP, LLC 1.5% 2,087,404 0% $208,740
GEODE CAPITAL MANAGEMENT, LLC 1% 1,492,903 +17% 0% $149,330
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.85% 1,211,629 -45% 0% $121,163
MILLENNIUM MANAGEMENT LLC 0.73% 1,051,846 -45% 0% $105,185
UBS Group AG 0.5% 718,924 -62% 0% $71,892
DEUTSCHE BANK AG\ 0.43% 622,226 0% 0% $62,223
Graham Capital Management, L.P. 0.4% 572,759 0% $57,276
STATE STREET CORP 0.39% 558,178 +7.6% 0% $55,818
Virtu Financial LLC 0.35% 496,288 +873% 0% $50,000
Lynx1 Capital Management LP 0.29% 410,500 0.01% $41,050
MARSHALL WACE, LLP 0.24% 337,389 -87% 0% $33,739
Hennion & Walsh Asset Management, Inc. 0.23% 327,137 +16% 0% $32,714
EQUITEC PROPRIETARY MARKETS, LLC 0.21% 300,600 0.14% $30,060
Bank of New York Mellon Corp 0.18% 253,573 +219% 0% $25,357
NORTHERN TRUST CORP 0.17% 245,144 +41% 0% $24,514
Rockefeller Capital Management L.P. 0.17% 241,897 -38% 0% $24,190
GTS SECURITIES LLC 0.14% 200,009 0% $20,001
MORGAN STANLEY 0.12% 178,474 -75% 0% $17,847

Institutional Holders of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 58,883,039 $5,929,909 -$23,764,068 $0.10 50
2025 Q3 94,763,328 $57,199,408 +$5,274,176 $0.60 69
2025 Q2 88,058,885 $27,371,087 -$7,459,469 $0.31 72
2025 Q1 106,044,815 $51,845,704 -$6,334,916 $0.49 89
2024 Q4 115,065,005 $98,537,797 -$63,025,089 $0.86 116
2024 Q3 112,721,874 $960,819,113 +$78,176,113 $8.50 125
2024 Q2 103,226,978 $481,702,267 +$36,985,908 $4.67 92
2024 Q1 93,958,967 $638,614,949 +$241,302,453 $6.80 88
2023 Q4 61,449,532 $205,844,085 +$29,840,415 $3.35 83
2023 Q3 42,970,428 $106,996,842 +$29,101,733 $2.49 54
2023 Q2 31,465,661 $40,275,555 +$15,796,729 $1.28 38
2023 Q1 19,276,965 $15,634,509 -$232,317 $0.81 34
2022 Q4 19,679,561 $15,064,959 -$2,201,503 $0.76 37
2022 Q3 22,671,560 $21,085,673 -$3,749,758 $0.93 38
2022 Q2 26,706,667 $25,318,845 +$12,989,524 $0.95 46
2022 Q1 12,347,239 $26,037,310 -$34,487,329 $2.11 68
2021 Q4 14,922,342 $133,548,279 -$7,772,547 $8.95 67
2021 Q3 15,108,904 $250,903,236 -$6,255,939 $16.60 66
2021 Q2 15,367,633 $319,342,764 +$10,194,603 $20.78 68
2021 Q1 14,854,223 $278,593,752 +$51,374,327 $18.76 66
2020 Q4 12,104,777 $266,428,658 -$1,610,604 $22.01 67
2020 Q3 12,195,771 $253,182,315 -$6,258,655 $20.76 66
2020 Q2 11,427,491 $412,583,649 +$78,213,106 $36.15 71
2020 Q1 9,645,977 $315,329,165 +$155,281,170 $32.69 62
2019 Q4 4,991,742 $136,175,281 +$71,201,517 $27.28 45
2019 Q3 2,395,520 $26,326,659 +$2,265,568 $10.99 29
2019 Q2 2,195,975 $18,095,000 +$18,095,000 $8.24 13

Sponsored